- Trials with a EudraCT protocol (56)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
56 result(s) found for: Model for End Stage Liver Disease.
Displaying page 1 of 3.
EudraCT Number: 2015-000963-15 | Sponsor Protocol Number: MATCH0.1 | Start Date*: 2016-01-19 | |||||||||||
Sponsor Name:University of Edinburgh [...] | |||||||||||||
Full Title: MAcrophage Therapy for Liver Cirrhosis (MATCH) | |||||||||||||
Medical condition: Liver Cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005012-42 | Sponsor Protocol Number: 747-302 | Start Date*: 2016-01-05 | |||||||||||
Sponsor Name:Intercept Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 4, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis. The COBALT S... | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Prematurely Ended) AT (Prematurely Ended) BE (Completed) DK (Prematurely Ended) FI (Prematurely Ended) GB (GB - no longer in EU/EEA) EE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) FR (Ongoing) DE (Completed) BG (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010335-41 | Sponsor Protocol Number: RRK3728 | Start Date*: 2009-06-30 | |||||||||||||||||||||||||||||||
Sponsor Name:University of Birmingham | |||||||||||||||||||||||||||||||||
Full Title: A MULTICENTRE, PHASE II, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF REPEATED AUTOLOGOUS INFUSIONS OF G-CSF MOBILISED CD133+ BONE MARROW STEM CELLS IN PATIENTS WITH CIRRHOSIS | |||||||||||||||||||||||||||||||||
Medical condition: Liver Cirrhosis | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004986-38 | Sponsor Protocol Number: 337HNAS20011 | Start Date*: 2022-01-04 | |||||||||||
Sponsor Name:Inventiva S.A. | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatiti... | |||||||||||||
Medical condition: Non-alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) AT (Completed) HU (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003051-11 | Sponsor Protocol Number: HEP102-DHELIVER | Start Date*: 2019-12-04 | |||||||||||
Sponsor Name:Promethera Therapeutics | |||||||||||||
Full Title: Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER | |||||||||||||
Medical condition: Cirrhotic patients who are hospitalized for Acute on chronic liver failure (ACLF), ACLF combines an acute deterioration of liver function in an individual with pre-existing chronic liver disease a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) LV (Trial now transitioned) LT (Trial now transitioned) SK (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Trial now transitioned) PL (Trial now transitioned) PT (Completed) EE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) SI (Completed) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023688-16 | Sponsor Protocol Number: C-III-002 | Start Date*: 2011-01-27 | ||||||||||||||||
Sponsor Name:CESAR Central European Society for Anticancer Drug Research-EWIV | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Parallel Group Study of Patients Treated with Paclitaxel with Standard Dosing versus Pharmacokinetic Guided Dose Adjustment in Patients with Advanced NSCLC | ||||||||||||||||||
Medical condition: Stage III-IV Non Small Cell Lung Cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001762-13 | Sponsor Protocol Number: 747-401 | Start Date*: 2018-08-01 |
Sponsor Name:Intercept Pharmaceuticals, Inc. | ||
Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepa... | ||
Medical condition: Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) HU (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-001139-22 | Sponsor Protocol Number: POPH | Start Date*: 2011-06-29 | |||||||||||
Sponsor Name:Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie | |||||||||||||
Full Title: AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY | |||||||||||||
Medical condition: Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005851-40 | Sponsor Protocol Number: TPL104054 | Start Date*: 2008-05-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with C... | |||||||||||||
Medical condition: Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) FR (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001983-31 | Sponsor Protocol Number: GT-031 | Start Date*: 2021-05-04 | ||||||||||||||||
Sponsor Name:Galectin Therapeutics Inc. | ||||||||||||||||||
Full Title: A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Es... | ||||||||||||||||||
Medical condition: Esophageal Varices in NASH Cirrhosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000821-37 | Sponsor Protocol Number: GS-US-416-2124 | Start Date*: 2017-02-06 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic H... | |||||||||||||
Medical condition: Alcoholic Hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003912-72 | Sponsor Protocol Number: H3E-MC-S103a | Start Date*: 2007-10-31 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company Limited | ||||||||||||||||||
Full Title: A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell... | ||||||||||||||||||
Medical condition: Patients with histological or cytological diagnosis of nonsquamous NSCLC with locally advanced or metastatic disease. Patients must have failed only one prior chemotherapy regimen and must be consi... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003916-29 | Sponsor Protocol Number: TREASURE | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |||||||||||||
Full Title: - TREASURE- Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease: a randomized, open-label, multicenter phase II study | |||||||||||||
Medical condition: Small cell lung cancer extensive disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004754-15 | Sponsor Protocol Number: 3152-201-002 | Start Date*: 2017-06-05 | |||||||||||
Sponsor Name:Tobira Therapeutics, Inc., a subsidiary of Allergan plc | |||||||||||||
Full Title: Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) | |||||||||||||
Medical condition: Liver fibrosis in Subjects with Nonalcoholic Steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) ES (Prematurely Ended) HU (Prematurely Ended) AT (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001240-61 | Sponsor Protocol Number: allo-APZ2-ACLF-II-01 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:RHEACELL GmbH & Co. KG | |||||||||||||
Full Title: An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF) | |||||||||||||
Medical condition: Acute-on-Chronic Liver Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001436-10 | Sponsor Protocol Number: INCB18424-266 | Start Date*: 2015-02-26 | |||||||||||||||||||||||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||||||||||||||||||||||
Full Title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small C... | |||||||||||||||||||||||||||||||||
Medical condition: Nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: IT (Completed) DK (Prematurely Ended) ES (Prematurely Ended) NL (Completed) PT (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002325-38 | Sponsor Protocol Number: A4250-008 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Albireo AB | |||||||||||||
Full Title: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2) | |||||||||||||
Medical condition: Progressive Familial Intrahepatic Cholestasis Types 1 and 2 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) ES (Prematurely Ended) IT (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004328-12 | Sponsor Protocol Number: Europe | Start Date*: 2015-01-23 | |||||||||||
Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH | |||||||||||||
Full Title: Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trial | |||||||||||||
Medical condition: Patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002194-22 | Sponsor Protocol Number: A-97-52030-270 | Start Date*: 2014-01-14 | |||||||||||
Sponsor Name:Ipsen Limited | |||||||||||||
Full Title: A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progr... | |||||||||||||
Medical condition: Symptoms of Neuro Endocrine tumours | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000581-38 | Sponsor Protocol Number: 17/0894 | Start Date*: 2019-07-29 | |||||||||||
Sponsor Name:University College London Comprehensive Clinical Trials Unit | |||||||||||||
Full Title: ASEPTIC: Primary Antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis | |||||||||||||
Medical condition: Spontaneous bacterial peritonitis infection in patients with advanced liver disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
